Sakae Naa Has No Mitragynine. So Why Is Everyone Asking About Drug Tests?

TL;DR: Sakae Naa (Combretum quadrangulare) has no mitragynine and has almost no CNS research at all. Standard drug panels aren't looking for anything in it, and the real risk is products spiked with other things.

Search PubMed for Combretum quadrangulare and you get around 19 papers. Not 19 pages. Nineteen results, total, for a plant that has been sold across the United States for years. Read through them and the pattern is immediate: liver protection in mice, alpha-glucosidase inhibition, anti-inflammatory work on skin, cholesterol-related enzyme studies, triterpene isolation. There is no receptor binding study. There is no analgesia paper. There is no central nervous system pharmacology at all.

That gap is the whole story of Sakae Naa and drug testing, and it runs in a direction most people do not expect.

What the plant contains

The phytochemistry on Combretum quadrangulare is genuinely well characterized, even if the pharmacology is thin. The seeds and leaves are dominated by cycloartane-type triterpenoids, a structural family that includes the quadranosides and combretanosides named after the plant itself. A 1999 paper in the Journal of Natural Products described thirteen novel cycloartane-type triterpenes from this single species. More have been isolated since, including work on Vietnamese-grown material published in 2022.

Alongside the triterpenoids sit flavonoids and flavones, including combretol, an O-methylated flavonol. Vietnamese researchers have isolated several flavones from the leaves. There are gallic acid derivatives. There are the usual polyphenols you would expect from a Combretaceae species.

What you do not find, anywhere in that literature, is mitragynine. You do not find 7-hydroxymitragynine, speciogynine, paynantheine, or any of the corynanthe-type indole alkaloids that define Mitragyna speciosa. Those alkaloids are a Rubiaceae trait. Sakae Naa is not in that family, not in that genus, not chemically adjacent to it in any meaningful way.

Triterpenoids and indole alkaloids are different molecular worlds. A triterpene glycoside is a large sugar-decorated hydrocarbon skeleton. An indole alkaloid is a nitrogen-containing ring system. An antibody raised against one has no structural reason to recognize the other.

The traditional record points somewhere else entirely

The plant has a long documented history in Southeast Asia, and almost none of it involves the nervous system. PROSEA, the standard reference on Southeast Asian plant resources, records the seeds being widely used as a vermifuge and for intestinal complaints. Leaves and roots appear in poultices for wounds and boils. In Indochina and Vietnam the plant shows up in records relating to biliary fever.

Worms and the liver. That is the traditional use profile. The modern laboratory work has largely followed those same threads, which is why hepatoprotective screening and antiparasitic screening dominate the small body of published research on the species.

The kratom-alternative framing is recent, commercial, and Western. It exists because kratom is banned or restricted in some states and countries, and a market appeared for anything grown in the same part of the world. The FDA added Sakae Naa to import alert 54-18 in July 2021, listing it as a new dietary ingredient without adequate safety information. Trade press covering that action noted there was little authoritative public information on the herb, and that most claims about it came from marketing rather than research.

Standard panels are not looking for it

The mechanics are simple. A 5-panel urine screen typically covers amphetamines, cocaine metabolite, opiates, PCP, and THC. A 10-panel adds things like benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone. A 12-panel extends further into oxycodone, buprenorphine, and similar targets.

Every one of those assays is an antibody built to recognize a specific drug or class of structurally related drugs. None of them were designed against triterpene glycosides or flavonoids. Those compounds are not drug-like in the relevant sense, they are not scheduled, and there is no commercial or forensic reason anyone would build a panel to catch them.

Worth knowing: kratom itself does not appear on these panels either. Mitragynine and 7-hydroxymitragynine are chemically distinct from morphine and its relatives and do not cross-react with standard opiate immunoassays. Detecting kratom requires a dedicated assay, ordered separately, typically screening by immunoassay around a 5 ng/mL cutoff and confirming by LC-MS/MS near 1 ng/mL. Labcorp runs one under test code 791750.

If someone orders that mitragynine panel, pure Sakae Naa material has nothing in it for the assay to find. The target analyte is not present in the plant. This is not a probability statement, it is a chemistry statement.

So where does the real risk sit

In the product, not the plant.

The kratom-adjacent market has a documented adulteration problem, and the analytical evidence on it has gotten sharp. A 2025 study in the Journal of AOAC International analyzed eight commercial products across five brands sold as kratom. They contained 7-hydroxymitragynine at 22 to 75 mg/g. Authentic kratom leaf, for comparison, showed no detectable 7-OH and carries mitragynine around 11.8 mg/g. The chromatograms showed peaks absent from native leaf material, which the authors read as byproducts of synthetic conversion rather than anything grown. Even identical batches varied: tablets ran 16.0 to 18.9 mg of 7-OH each.

The FDA and DEA have moved against concentrated and semi-synthetic 7-OH products, with warning letters in 2025 and scheduling activity following. The agency has been explicit that those actions target concentrated and synthetic material rather than leaf containing naturally occurring trace levels.

Now connect that to Sakae Naa. The plant has no published CNS pharmacology. It is being sold into a market where buyers expect something. That combination creates an obvious commercial temptation for an unscrupulous seller, and it is exactly the scenario where a product labeled as one botanical contains something else. A mitragynine panel would catch that. An opioid panel would catch a synthetic opioid adulterant. Neither result would reflect the plant on the label.

The drug test question about Sakae Naa turns out to be a supply chain question wearing a chemistry costume.

What that means practically

If you are subject to testing of any kind, the useful questions are about the product rather than the species. What is actually in the bag? Has the material been identified? Is there anything in it besides the single botanical named on the label? A seller who cannot tell you what the material is has told you something.

And if a specific test result matters to your job, your treatment program, or a legal situation, talk to the people administering the test or to a medical professional. Published cutoffs and panel compositions vary between labs and programs.

At Healing Herbals we keep it simple: single-ingredient botanical material, identified and tested, with nothing added that is not on the label. Browse the collection here, including our Sakae Naa Extract Resin.

This article is for informational and educational purposes only. It is not medical advice, and nothing here is intended to diagnose, treat, cure, or prevent any condition, or to guide any decision about drug testing. Consult a qualified healthcare professional with questions about your own situation.

Keep reading: Kratom and Drug Tests: The False Positive Runs Both Ways and Cat's Claw Shares a Family Tree With Kratom.